Objective: To report a case of esophageal cancer in an adult patient with cystic fibrosis (CF) and review the relationship between these 2 diseases.

Case Report: A 40-year-old man with CF presented with worsening epigastric pain, weight loss, and upper gastrointestinal (GI) bleeding. Endoscopy revealed innumerable masses in the distal esophagus. The workup revealed esophageal adenocarcinoma metastatic to the liver and the lungs.

Discussion: Abnormal mucous secretions in CF patients impair the innate GI mucosal barriers. The incidence of both gastroesophageal reflux disease and GI malignancies is higher in patients with CF. Patients with CF now survive long enough to potentially experience the consequences of long-term acid exposure, including esophagitis, Barrett esophagus, and esophageal cancer.

Conclusion: Our case report adds to a small but growing body of evidence that CF is a significant risk factor for GI malignancies, including esophageal adenocarcinoma. Controlled studies are needed to determine whether a causal relationship truly exists.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684335PMC

Publication Analysis

Top Keywords

esophageal adenocarcinoma
12
40-year-old man
8
cystic fibrosis
8
esophageal
5
adenocarcinoma 40-year-old
4
man cystic
4
fibrosis coincidence
4
coincidence not?
4
not? objective
4
objective report
4

Similar Publications

The management of esophageal cancer (EC) remains a significant clinical challenge, particularly in optimizing therapeutic strategies for different stages and subgroups. This study assessed the impact of preoperative radiochemotherapy (CRT) on clinical staging and identified subgroups for whom definitive CRT (dCRT) may provide a favorable alternative to surgery. Sixty-one patients with esophageal adenocarcinoma or squamous cell carcinoma were enrolled.

View Article and Find Full Text PDF

PLASMA: Partial LeAst Squares for Multiomics Analysis.

Cancers (Basel)

January 2025

Department of Biostatistics, Data Science, and Epidemiology, School of Public Health, Georgia Cancer Center at Augusta University, Augusta, GA 30912, USA.

: Recent growth in the number and applications of high-throughput "omics" technologies has created a need for better methods to integrate multiomics data. Much progress has been made in developing unsupervised methods, but supervised methods have lagged behind. : Here we present the first algorithm, PLASMA, that can learn to predict time-to-event outcomes from multiomics data sets, even when some samples have only been assayed on a subset of the omics data sets.

View Article and Find Full Text PDF

Background: Adenocarcinoma of the esophagogastric junction (AEGJ) is a highly aggressive tumor that frequently metastasizes to the liver. Understanding the cellular and molecular mechanisms that drive this process is essential for developing effective therapies.

Methods: We employed single-cell RNA sequencing to analyze the tumor heterogeneity and microenvironmental landscape in patients with AEGJ liver metastases.

View Article and Find Full Text PDF

Background: Neoadjuvant Chemoradiation (nCRT) has been shown to improve survival in patients with Esophageal Adenocarcinoma (EAC). The objective of this study is to assess the patient characteristics associated with tumor downstaging in a large national database. Additionally, we evaluated surgical approach and change in clinical versus pathological staging as predictors of patient survival.

View Article and Find Full Text PDF

Surgical resection and lymphadenectomy are the mainstay of curative treatment for oesophagogastric cancer. In this study we evaluate the results of intravascular methylene blue injection into oesophagectomy and gastrectomy specimens as a tool to increase lymph node detection. A prospective and descriptive study was run on 24 patients (11 oesophagus, 13 stomach cases).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!